# Surgery Partners, Inc. (SGRY) Stock Analysis: A 41% Upside Potential and Analysts’ Consensus

- Link: https://www.directorstalkinterviews.com/surgery-partners-inc-sgry-stock-analysis-a-41-upside-potential-and-analysts-consensus/4121205342
- Published: 2025-07-01T10:36:15+01:00
- Author: Madison Wilson

Surgery Partners, Inc. (NASDAQ: SGRY) has captured the attention of investors with
its dynamic presence in the healthcare sector, particularly in the medical care 
facilities industry. Headquartered in Brentwood, Tennessee, the company provides
a range of surgical services through its network of ambulatory surgery centers and
hospitals across the United States. As of today, the company boasts a market capitalization
of $2.85 billion.

### Price and Valuation Metrics

Currently, SGRY is trading at $22.23, reflecting a slight increase of 0.28% from
its previous close. The stock’s 52-week range of $19.30 to $33.69 indicates volatility
and potential for both risk and reward. However, with a forward P/E ratio of 20.60,
the valuation suggests that investors are optimistic about the company’s future 
earnings potential. The lack of a trailing P/E ratio and PEG ratio, as well as Price/
Book and Price/Sales data, may require investors to delve deeper into qualitative
assessments.

### Performance and Financial Strength

Surgery Partners has demonstrated a solid revenue growth of 8.20%, a promising indicator
in a competitive industry. However, the company’s net income remains unavailable,
and with an EPS of -1.53, this may raise concerns about profitability. The negative
return on equity of -0.35% further suggests challenges in efficiently utilizing 
shareholder funds.

On a positive note, Surgery Partners reports a robust free cash flow of approximately
$142.6 million, which underscores its ability to generate cash from operations. 
This liquidity is crucial for the company’s ongoing investments and potential debt
servicing.

### Analyst Ratings and Potential Upside

The investment community has shown confidence in Surgery Partners, with 9 buy ratings
and 3 hold ratings, and no sell recommendations. This consensus reflects a positive
outlook, further emphasized by the target price range of $24.00 to $36.00. The average
target price of $31.36 suggests a potential upside of 41.09% from the current price
levels, a compelling proposition for growth-oriented investors.

### Technical Indicators

Technically, SGRY’s 50-day moving average of $22.39 and 200-day moving average of
$24.62 provide a mixed picture. The Relative Strength Index (RSI) at 69.63 suggests
that the stock is nearing overbought territory, which could signal a potential pullback
or consolidation. However, the MACD and Signal Line, both showing negative values,
indicate a bearish trend that investors should monitor closely.

### Strategic Positioning and Growth Prospects

Surgery Partners’ strategic focus on non-emergency surgical procedures across multiple
specialties positions it well in a niche market. The company’s comprehensive service
offerings, including orthopedics, ophthalmology, and gastroenterology, cater to 
a growing demand for outpatient surgical services. This market demand, coupled with
potential healthcare policy shifts favoring cost-effective surgical solutions, could
bolster Surgery Partners’ growth trajectory.

As the company continues to expand its network and enhance service capabilities,
investors should watch for operational improvements and strategic acquisitions that
could drive future earnings. While current financial metrics may pose challenges,
the company’s free cash flow strength provides a cushion for strategic initiatives.

For investors considering a stake in the healthcare sector, Surgery Partners presents
a unique blend of growth potential and strategic positioning. With a significant
upside projected by analysts, SGRY warrants attention, albeit with a mindful eye
on profitability trends and technical signals.

Share on: